Latest Research News from the Foundation for Women's Cancer and Society of Gynecologic Oncology

Real-world treatment with liso-cel showed a broad spectrum of outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Treatment with acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over standard-of-care chemoimmunotherapy in patients with treatment-naive CLL.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Treatment with epcoritamab alone demonstrated deep responses in heavily pretreated patients with CLL, according to the expansion and optimization cohorts in the EPCORE CLL-1 trial.

“By addressing these issues, we can ensure that all patients, regardless of their socioeconomic status, have the opportunity to benefit from potentially curative treatments,” one expert says.